PMV Pharma Q2 net loss $18.1M; completes PYNNACLE enrollment, NDA planned Q1 2027

PMV Pharmaceuticals, Inc.

2026-Q2 EPS reported -$0.68

Net loss $18.1M for Q2 2026 vs $21.2M in Q2 2025; R&D expenses down to $14.7M from $18.4M.
Enrollment completed for primary analysis in Phase 2 monotherapy portion of PYNNACLE trial for platinum-resistant/refractory ovarian cancer.
NDA submission for rezatapopt accelerated approval planned Q1 2027.
Cash $79.4M as of June 30, 2026, down from $112.9M at Dec 31, 2025; runway through Q2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.